Table 1.
Baseline characteristics of study population
| Baseline parameter | Value |
|---|---|
| Age (years); mean (SD) | 52.8 (11.1) |
| Age ≥ 50 years, N (%) | 1296 (64.6) |
| Sex, N (%) | |
| Male | 982 (48.9) |
| Female | 1025 (51.1) |
| Diabetes duration, months (IQR) | 26.0 (3.9–65.6) |
| ≥ 24 months, N (%) | 472 (23.5) |
| Body weight, kg (SD) | 75.8 (15.0) |
| BMI, kg/m2 (SD) | 28.1 (4.4) |
| Obesity (≥ 25 kg/m2), N (%) | 1092 (76.2) |
| Waist circumference, cm (SD) | 92.2 (10.2) |
| SBP, mmHg (SD) | 128.1 (14.2) |
| DBP, mmHg (SD) | 77.8 (10.3) |
| FPG, mg/dl (SD) | 166.2 (48.8) |
| PPG, mg/dl (SD) | 233.1 (80.4) |
| HbA1c, % (SD) | 8.1 (1.3) |
| Serum creatinine (mg/dl) | 0.8 (0.2) |
| eGFR, ml/min/1.73 m2 (SD) | 95.4 ± 15.6 |
| Diabetes-related complications, N (%) | |
| No | 1559 (77.7) |
| Yes | 448 (22.3) |
| Manner of dapagliflozin use, N (%) | |
| Add-on | 1069 (53.3) |
| Switch | 936 (46.6) |
| Unknown | 2 (0.1) |
| Anti-diabetic medication, N (%) | |
| Monotherapy | 75 (3.7) |
| Dual therapy | 551 (27.4) |
| Triple therapy or more | 1004 (50.0) |
| Add on to insulin | 1025 (18.8) |
| Concomitant anti-diabetic medication, N (%) | |
| Metformin | 1813 (90.3) |
| Sulfonylureas | 752 (37.5) |
| Thiazolidinediones | 215 (10.7) |
| DPP-4 inhibitor | 820 (40.8) |
| Injection | 425 (21.2) |
Data for continuous variables are expressed as mean ± standard deviation (SD) and for categorical variables as number (percent)
IQR interquartile range, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, PPG postprandial glucose, HbA1c glycated hemoglobin